Navigation Links
Tengion Presents New Data Supporting its Organ Regeneration Platform™ at 8th Annual Meeting of the International Society for Stem Cell Research
Date:6/17/2010

EAST NORRITON, Pa., June 17 /PRNewswire-FirstCall/ -- Tengion Inc. (Nasdaq: TNGN) today announced that it has presented new preclinical data at the 8th Annual Meeting of the International Society for Stem Cell Research (ISSCR) being held June 16-19 in San Francisco.  These data, highlighted during the meeting's poster session on June 16, show the important distinction between adipose-derived smooth muscle cells (SMCs) and mesenchymal stem cells (MSCs).  The Tengion data demonstrate that SMC's sourced from adipose tissue, which have been demonstrated to promote regeneration of tubular tissues and hollow organs, have protein and gene expression profiles distinct from those generated by MSCs.  Tengion's Neo-Urinary Conduit™, currently in Phase 1 clinical development, is utilizing the Tengion's proprietary adipose-derived SMC technology.

"Our continued generation of key preclinical data further demonstrates mechanisms of natural regeneration promoted by Tengion's technology platform," stated Tim Bertram, D.V.M., Ph.D., Senior Vice President of Science and Technology for Tengion.  Tengion's lead product candidate, the Neo-Urinary Conduit, is currently in an open-label, single arm Phase I clinical trial in patients with bladder cancer.  The Neo-Urinary Conduit is an autologous – made from a patient's own cells – implant that is intended to catalyze the regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal.

The ISSCR data presentation is available on Tengion's website at '/>"/>

SOURCE Tengion Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Preclinical Efficacy Data Demonstrate Ability of Tengions Neo-Bladder Augment to Restore Bladder Function
2. Tengion to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
3. Tengion Appoints Jeff Randall to Board of Directors
4. Tengion Announces European Orphan Drug Designation for Neo-Bladder Augment
5. Tengion Appoints Mark Stejbach Vice President of Marketing & Commercial Planning
6. Tengion Scientists Publish Positive Preclinical Findings With Neo-Organ Demonstrating Long-term Durability and Growth With Skeletal Maturation
7. Tengion Featured as Model of Innovation and Success at 35th Anniversary Celebration of the National Venture Capital Association
8. Tengion Announces Second Closing of Series C Financing
9. Tengion to Present at the Piper Jaffray 20th Annual Healthcare Conference
10. Tengion Presents New Data Supporting Key Urologic and Kidney Programs at 16th Annual Meeting of the International Society for Cellular Therapy
11. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Earlier this year in a June 24 international ... Adult Stem Cell Technology Center, LLC ( ASCTC ) ... unique property of adult tissue stem cells. His ... the Past, Important for the Future,” embodied the essence ... the address at the 4th World Congress on Cell ...
(Date:12/24/2014)... 2014 The report provides ... its definition, classification, application and industry overview. ... process, and product cost structure. Production is ... analysis also covers upstream raw materials, equipment, ... trend and proposals. In the end, the ...
(Date:12/24/2014)... -- China Biologic Products, Inc. (NASDAQ: CBPO, "China ... plasma-based biopharmaceutical company in China ... Taibang Biological Products Co. Ltd., has received Good ... and Drug Administration (the "CFDA") for its new ... the Company,s public filings, the CFDA inspected this ...
(Date:12/24/2014)... Dec. 23, 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... filed a Clinical Trial Application (CTA) with the ... Agency (MHRA) seeking regulatory approval to initiate clinical trials ... Citrate. Contingent on the Company receiving CTA ... I trial to assess the safety, tolerability and dose ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... ... listed below, ST. LOUIS, June 13 ETHEX Corporation announced ... mg extended release tablets, and specific lots of morphine,sulfate 30 mg ... oversized tablets. Oversized tablets may contain as,much as two times the ...
... Conn., June 13 Alexion,Pharmaceuticals, Inc. (Nasdaq: ... President and Chief Financial Officer of Alexion,Pharmaceuticals, will ... Stock,Conference in Chicago at 9:10 a.m., local time ... An audio webcast of Mr. Sinha,s remarks will ...
... 13 Best Practices, LLC,s latest,benchmarking study explains ... CI operations while working within defined,guidelines., Particular ... is being,collected, and how CI groups work within ... collection that are in the best interests of,the ...
Cached Biology Technology:ETHEX Corporation Voluntarily Recalls Specific Lots of 30 mg. and 60 mg. Morphine Sulfate Extended Release Tablets Due to the Potential for Oversized Tablets 2ETHEX Corporation Voluntarily Recalls Specific Lots of 30 mg. and 60 mg. Morphine Sulfate Extended Release Tablets Due to the Potential for Oversized Tablets 3ETHEX Corporation Voluntarily Recalls Specific Lots of 30 mg. and 60 mg. Morphine Sulfate Extended Release Tablets Due to the Potential for Oversized Tablets 4Pharmaceutical Competitive Intelligence Excellence: Optimizing Data Collection with Approved Guidelines 2
(Date:12/10/2014)... 9, 2014     ...   Jifflenow, a ... solutions for business-to-business (B2B) events, today announced a ... mobile near-field communication (NFC), Bluetooth low energy (BLE), ... http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate its ...
(Date:12/3/2014)...   Marvin Test Solutions , a trusted ... military, aerospace, and manufacturing organizations, today announced the ... TS-900 PXI semiconductor test platform . The TS-960 ... to customers at a fraction of the footprint ... "Our semiconductor customers asked for ...
(Date:11/21/2014)... MOUNTAIN VIEW, Calif. , Nov. 20, 2014 /PRNewswire/ ... for higher driver efficiency are piloting the North American ... the number of accidents growing, gesture recognition systems that ... will make a mark in the industry. ... of the Automotive Gesture Recognition Market in ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
... available amount of fossil fuels is limited and their ... The generation of fuels from biomass as an alternative ... Chemie , Johannes A. Lercher and his team at ... catalytic process that allows the effective conversion of biopetroleum ...
... KAN. -- A Kansas State University graduate student sees the ... Smith, master,s student in civil engineering, Independence, Mo., is working ... to improve the quality of unpaved roads throughout Kansas. ... in Kansas are unpaved, Smith said. "One of the ...
... advancing field of tissue injury and repair has an ... will report the latest research findings, innovative wound care ... skin and tissue regeneration to optimize patient outcomes. The ... is an Official Publication of the Wound Healing ...
Cached Biology News:Algae for your fuel tank 2The path less traveled: Research is driving solutions to improve unpaved roads 2The path less traveled: Research is driving solutions to improve unpaved roads 3New publication fosters improved wound care for ulcers, limb salvage, burns, trauma, and more 2